Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice
- PMID: 17483354
- DOI: 10.1158/0008-5472.CAN-06-4260
Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice
Erratum in
- Cancer Res. 2007 Jun 15;67(12):5998
Abstract
Selective replication of oncolytic viruses in tumor cells provides a promising approach for the treatment of human cancers. One of the limitations observed with oncolytic viruses currently used in the treatment of solid tumors is the inefficient spread of virus throughout the tumor mass following intratumoral injection. Data are presented showing that oncolytic adenoviruses expressing the relaxin gene and containing an Ad5/Ad35 chimeric fiber showed significantly enhanced transduction and increased virus spread throughout the tumor when compared with non-relaxin-expressing, Ad5-based viruses. The increased spread of such viruses throughout tumors correlated well with improved antitumor efficacy and overall survival in two highly metastatic tumor models. Furthermore, nonreplicating viruses expressing relaxin did not increase metastases, suggesting that high level expression of relaxin will not enhance metastatic spread of tumors. In summary, the data show that relaxin may play a role in rearranging matrix components within tumors, which helps recombinant oncolytic adenoviruses to spread effectively throughout the tumor mass and thereby increase the extent of viral replication within the tumor. Expressing relaxin from Ad5/Ad35 fiber chimeric adenoviruses may prove a potent and novel approach to treating patients with cancer.
Similar articles
-
Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.Clin Cancer Res. 2008 Jun 15;14(12):3933-41. doi: 10.1158/1078-0432.CCR-07-4732. Clin Cancer Res. 2008. PMID: 18559615
-
Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy.J Natl Cancer Inst. 2006 Oct 18;98(20):1482-93. doi: 10.1093/jnci/djj397. J Natl Cancer Inst. 2006. PMID: 17047197
-
A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.Cancer Res. 2007 Sep 15;67(18):8783-90. doi: 10.1158/0008-5472.CAN-07-0357. Cancer Res. 2007. PMID: 17875719
-
Oncolytic adenoviruses - selective retargeting to tumor cells.Oncogene. 2005 Nov 21;24(52):7775-91. doi: 10.1038/sj.onc.1209044. Oncogene. 2005. PMID: 16299537 Review.
-
Adenovirus-based therapy for prostate cancer.Curr Opin Mol Ther. 2010 Aug;12(4):421-31. Curr Opin Mol Ther. 2010. PMID: 20677093 Review.
Cited by
-
Genetic Modifications That Expand Oncolytic Virus Potency.Front Mol Biosci. 2022 Jan 26;9:831091. doi: 10.3389/fmolb.2022.831091. eCollection 2022. Front Mol Biosci. 2022. PMID: 35155581 Free PMC article. Review.
-
Tumor Restrictions to Oncolytic Virus.Biomedicines. 2014 Apr 17;2(2):163-194. doi: 10.3390/biomedicines2020163. Biomedicines. 2014. PMID: 28548066 Free PMC article. Review.
-
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy.Clin Cancer Res. 2011 Mar 15;17(6):1362-72. doi: 10.1158/1078-0432.CCR-10-2213. Epub 2010 Dec 21. Clin Cancer Res. 2011. PMID: 21177410 Free PMC article.
-
Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors.BMC Cancer. 2012 Aug 23;12:366. doi: 10.1186/1471-2407-12-366. BMC Cancer. 2012. PMID: 22917220 Free PMC article.
-
The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.Cancer Gene Ther. 2014 Feb;21(2):68-73. doi: 10.1038/cgt.2013.85. Epub 2014 Jan 17. Cancer Gene Ther. 2014. PMID: 24434571
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical